FA
TNDM icon

Friess Associates’s Tandem Diabetes Care TNDM Stock Holding History

Friess Associates’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-467,861
Closed -$44.8M – 124
2020
Q4 		$44.8M Buy
467,861
+57,149
+14% +$5.89M 3.3% 2
2020
Q3 		$46.6M Sell
410,712
-14,055
-3% -$1.48M 4.04% 2
2020
Q2 		$42M Sell
424,767
-153,592
-27% -$12.3M 3.92% 2
2020
Q1 		$37.2M Sell
578,359
-48,866
-8% -$3.42M 3.71% 1
2019
Q4 		$37.4M Buy
627,225
+125,240
+25% +$7.72M 2.6% 3
2019
Q3 		$29.6M Sell
501,985
-7,891
-2% -$504K 2.29% 4
2019
Q2 		$32.9M Buy
509,876
+32,957
+7% +$2.13M 2.4% 3
2019
Q1 		$30.3M Sell
476,919
-111,302
-19% -$5.85M 2.22% 3
2018
Q4 		$22.3M Buy
588,221
+88,366
+18% +$3.12M 1.91% 8
2018
Q3 		$21.4M Buy
499,855
+391,855
+363% +$13.7M 1.49% 22
2018
Q2 		$2.38M Buy
+108,000
New +$1.33M 0.19% 95

Other funds holding TNDM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Friess Associates's TNDM Position: Q1 2021 in Review

Friess Associates sold out of Tandem Diabetes Care (TNDM) in Q1 2021, closing a stake of 467,861 shares — an estimated $44.8M sold.

Friess Associates first reported a position in TNDM in Q2 2018 and held it in 11 quarters. The position peaked at $46.6M in Q3 2020. 290 funds tracked by Wall St. Rank hold TNDM as of Q1 2021.

  • Friess Associates reported no remaining Tandem Diabetes Care position as of Q1 2021 after selling out during the quarter.
  • Friess Associates sold 467,861 Tandem Diabetes Care shares in Q1 2021, an estimated $44.8M.
  • Friess Associates first reported a position in Tandem Diabetes Care in Q2 2018 and held it in 11 quarters.
  • Friess Associates's Tandem Diabetes Care position peaked at $46.6M in Q3 2020.
  • 290 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2021.

Based on Friess Associates's 13F filing for Q1 2021, filed 14 May 2021.